Navigation Links
Vaccine Could Cut Bouts With Stomach Flu
Date:2/12/2008

Controlling quickly mutating noroviruses might mean yearly changes in formula

TUESDAY, Feb. 12 (HealthDay News) -- It may be possible to develop a vaccine to control noroviruses -- a common cause of stomach flu -- but it's likely a such a vaccine would have to be changed every year because the viruses evolve quickly to avoid attacks by the immune system, new research suggests.

Noroviruses infect cells after attaching to histo-blood group antigens (HBGA), molecules located on the surface of cells. HBGAs are a family of complex sugar molecules that exist in great variety among humans, according to background information in the study in the journal PLoS Medicine.

Ralph Baric, of the University of North Carolina at Chapel Hill, and his colleagues found this large variety of HBGAs contributes to recurrence of norovirus outbreaks, even among people who have previously been exposed to the virus and have developed antibodies against it.

The researchers analyzed noroviruses that caused several outbreaks and found that the viruses evolved to avoid attack by immune system antibodies.

Over time, some of the norovirus strains developed a shape that enabled them to bind other forms of HBGA. These viruses were then resistant to previously existing antibodies and able to infect cells carrying that particular form of HBGA. These viruses could then cause a new outbreak, with the cycle repeating itself, the researchers said.

Noroviruses, which can cause nausea, vomiting and diarrhea, are highly contagious. Most people recover within a few days, but the viruses can cause severe problems in very young and in old people. There is no specific treatment for norovirus infection.

More information

The U.S. Centers for Disease Control and Prevention has more about noroviruses.

'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Iomai Study Shows Self-Applied Travelers Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch
2. Meningitis vaccine study gets £200,000 boost
3. Tattooing Best Way to Deliver DNA Vaccines
4. Novel molecules developed at UB can boost vaccine potency
5. USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
6. Another Study Finds No Link Between MMR Vaccine and Autism
7. New hospital standards needed for pediatric flu vaccines
8. Experimental Vaccine Halts Prostate Cancer in Mice
9. Novel vaccine concept developed by scientists at the Wistar Institute
10. Mercury in Childhood Vaccines Excreted Quickly
11. Childhood Vaccines Save Lives, March Of Dimes Says
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vaccine Could Cut Bouts With Stomach Flu
Vaccine Could Cut Bouts With Stomach Flu
Breaking Medicine Technology:New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records 28EHRs 29 53831 1Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records 28EHRs 29 53831 2Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records 28EHRs 29 53831 3Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records 28EHRs 29 53831 4Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records 28EHRs 29 53831 5Former Microsoft Healthcare Executive Joins iMedExchange 53828 1Former Microsoft Healthcare Executive Joins iMedExchange 53828 2Gold Standard Elsevier Launches MedCounselor Consumer Drug Information Modules 53825 1Gold Standard Elsevier Launches MedCounselor Consumer Drug Information Modules 53825 2Gold Standard Elsevier Launches MedCounselor Consumer Drug Information Modules 53825 3